By analyzing the clinical data of patients with advanced breast cancer with bone metastasis admitted to our center from January 1, 2021 to February 28, 2023, this study aims to understand the real-world clinical diagnosis and treatment of breast cancer with bone metastasis, including the epidemiology of bone metastasis, screening and diagnosis methods, selection of clinical treatment methods, and occurrence of SRE. To explore the risk factors related to bone metastasis-free survival (BMFI). In addition, we will explore the use of quantitative analysis of CT values to evaluate bone metastases of breast cancer, aiming to provide a new method for imaging quantitative efficacy evaluation of bone metastases.
The specific contents of our research include the basic information of breast cancer patients with bone metastasis in the early stage, neoadjuvant therapy, surgery and postoperative pathology, and adjuvant therapy; The time and location of recurrence and metastasis, treatment plan, and information related to bone metastasis include time, location, diagnosis method, treatment, occurrence of SRE, and changes in CT values of bone lesions before and after drug treatment. The objective is to understand the risk factors of bone metastasis-free survival (BMFI) of breast cancer patients with bone metastases in the real world, provide evidence and data for clinical accurate screening, observe the CT value changes of bone lesions through imaging (CT quantitative), and explore a new method for evaluating the efficacy of bone metastases.
Study Type
OBSERVATIONAL
Enrollment
737
Zhejiang Cancer Hospital
Zhejiang, China
Bone metastasis-free interval (BMFI) of breast cancer patients with bone metastasis
Bone metastasis-free interval (BMFI) is the time between diagnosis of breast cancer and the onset of bone metastases
Time frame: From the diagnosis of breast cancer to the occurrence of bone metastasis，assessed up to 100 months
Number of participants with Clinical features of bone metastasis
Clinical characteristics of patients with bone metastasis include age, menstrual status, body mass index (BMI), presence or non-presence of underlying disease, tumor location, primary tumor size, number of lymph node metastases, TNM stage, pathologic type, histological classification, vascular thrombus invasion, estrogen receptor (ER) status, progesterone receptor (PR) status, and other factors. Human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 level, whether chemotherapy and radiotherapy, recurrence and metastasis time, recurrence and metastasis site.
Time frame: From the diagnosis of breast cancer to the conclusion of the study period，assessed up to 100 months
Changes of CT values of bone lesions before and after treatment with bone protective drugs
CT value selection method: A professional physician manually selected a region of interest (ROI) for a single bone metastatic lesion, and recorded the mean value of CT value, which was expressed in Hounsfield units (HU). The ROI difference of the same bone metastasis before and after treatment was not more than ±10mm2
Time frame: From the start of treatment with bone care drugs to 1 year
Patterns of bone metastasis in the center
The time of bone metastasis were included
Time frame: rom the diagnosis of breast cancer to the occurrence of bone metastasis,assessed up to 100 months
Occurrence of bone-related events
Skeleton-relative Events (SREs) include pathological fractures, spinal cord compression, bone surgery, and radiation therapy
Time frame: From the diagnosis of breast cancer to the occurrence of bone-related events，assessed up to 100 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.